Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 8

Results For "immuno"

769 News Found

Breakthrough in PsA: Taltz plus Zepbound show major gains for patients with obesity
R&D | January 09, 2026

Breakthrough in PsA: Taltz plus Zepbound show major gains for patients with obesity

This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures


Biocon Biologics to introduce three new oncology biosimilars, eyes $75 billion market opportunity
News | January 08, 2026

Biocon Biologics to introduce three new oncology biosimilars, eyes $75 billion market opportunity

The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies


GSK’s Exdensur wins Japanese nod for severe asthma
Drug Approval | January 08, 2026

GSK’s Exdensur wins Japanese nod for severe asthma

The approval follows robust data from the SWIFT and ANCHOR Phase III trials


ICMR & Panacea Biotec complete enrollment for India's first indigenous dengue vaccine phase 3 study
Clinical Trials | January 08, 2026

ICMR & Panacea Biotec complete enrollment for India's first indigenous dengue vaccine phase 3 study

DengiAll will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027


GSK’s Nucala approved in China for COPD with high eosinophils
Drug Approval | January 07, 2026

GSK’s Nucala approved in China for COPD with high eosinophils

Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL


Reimagining India’s Pharmaceutical Sector: From Global Supplier to Innovation Leader
Opinion | January 07, 2026

Reimagining India’s Pharmaceutical Sector: From Global Supplier to Innovation Leader

India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry


BioInvent’s experimental combo shows promise in hard-to-treat ovarian cancer
Clinical Trials | January 06, 2026

BioInvent’s experimental combo shows promise in hard-to-treat ovarian cancer

Pembrolizumab has shown meaningful benefit only when combined with chemotherapy


FibroBiologics moves experimental psoriasis therapy into FDA review
News | January 04, 2026

FibroBiologics moves experimental psoriasis therapy into FDA review

The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline


Biotium launches GlycoLiner kits for fast & selective cell surface glycoprotein labelling
News | January 03, 2026

Biotium launches GlycoLiner kits for fast & selective cell surface glycoprotein labelling

Biotium reports that GlycoLiner Labelling is fully covalent and compatible with standard fixation and permeabilization protocols


Diamyd Medical accelerates Phase 3 Type 1 diabetes trial following FDA guidance
Clinical Trials | December 31, 2025

Diamyd Medical accelerates Phase 3 Type 1 diabetes trial following FDA guidance

The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026